Meanwhile, the S&P BSE Sensex was down 70.62 points, or 0.37%, to 19,255.25.

On BSE, 2.10 lakh shares were traded in the counter as against an average daily volume of 1.75 lakh shares in the past one quarter.

The stock hit a high of Rs 57.60 and a low of Rs 53.75 so far during the day. The stock had hit a 52-week high of Rs 131.85 on 20 July 2012. The stock had hit a 52-week low of Rs 46.75 on 13 June 2013.

The stock is up 17.95% in two sessions from Rs 47.90 on Friday, 14 June 2013. The stock had underperformed the market over the past one month till 17 June 2013, falling 16.43% compared with the Sensex's 4.73% fall. The scrip had also underperformed the market in past one quarter, sliding 34.60% as against Sensex's 0.52% fall.

The small-cap pharmaceuticals company has an equity capital of Rs 70.45 crore. Face value per share is Rs 10.

Orchid Chemicals & Pharmaceuticals announced during market hours on Monday, 17 June 2013, that the company's oral formulations facility at Irungattukottai near Chennai was successfully inspected and accepted by the US Food and Drug Administration (USFDA) without any observations.

The Irungattukottai facility manufactures various types of dosage forms such as oral tablets and capsules in diverse dosage strengths and product categories.

Orchid Chemicals & Pharmaceuticals reported net loss of Rs 132.27 crore in Q4 March 2013, as against net profit of Rs 20.55 crore in Q4 March 2012. Revenue declined 45.36% to Rs 268.16 crore in Q4 March 2013 over Q4 March 2012.

Orchid Chemicals & Pharmaceuticals is involved in the development, manufacture and marketing of diverse bulk activities, formulations and nutraceuticals.